Valeo Pharma Inc.

KIRKLAND, A8 · CIK 0001904395 · Biotech · Acquired

Pharmaceutical therapeutics in respiratory, neurology, and oncology indications

valeopharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$787K
1 Form D · Jan 2022
57 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$787,400
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2151Denali Medical II, Inc.—$4.0M
2152KANNALIFE SCIENCES, INC.—$1.5M
2153QRKANSWER LLC——
2154Valeo Pharma Inc.—$787K
2155Falcon Therapeutics, Inc.—$700K
2156Mindset Pharma Inc.—$694K
2157Bitterroot Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 14 related persons
  • Guy-Paul AllardExecutive Officer
  • Maureen BreenanDirector
  • Michelle BrienExecutive Officer
  • Frederic FasanoDirector · Executive Officer
  • Vincent HogueDirector
  • Nelly KomariExecutive Officer
  • Richard MackayDirector · Executive Officer
  • Luc MainvilleExecutive Officer
  • Helen SaviukExecutive Officer
  • Steve SaviukDirector · Executive Officer
  • Jeff SkinnerExecutive Officer
  • Nathalie TherrienExecutive Officer
  • Michel TrudeauDirector
  • Michael WellsDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.